145.77 USD
▼-0.81-0.55%
盘后 147.00 +0.84%
2026-11-19
市值
$2.09B
市盈率
—
EPS
-5.57
股息率
—
52 周区间
72.23 – 179.95
成交量
150.43K
Beta
—
目标价
233.44
52W 低 72.2352W 高 179.95
价格走势
公司简介
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ...